PharmaShots

MAY 5, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EC’s Marketing Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease Date: May 05, 2023 | Tags: Chiesi Global Rare Diseases, Protalix BioTherapeutics, PRX-102, pegunigalsidase alfa, Fabry Disease, Regulatory, EC, Marketing Authorization Kinoxis Therapeutics (..)

FDA 40

FDA 40

PharmaShots

APRIL 21, 2023

Oblato Reports the First Patient Enrolment of OKN-007 in the P-I Clinical Trial for Recurrent High-Grade Glioma Date: Apr 21, 2023 | Tags: Oblato, OKN-007, Recurrent High-Grade Glioma, Regulatory, Henry Ford Health System CARsgen's CT041 Receives the US FDA’s IND Clearance for the Postoperative Adjuvant Therapy of Pancreatic Cancer Date: (..)

FDA 40

FDA Labelling 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 24, 2023

Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive

FDA 40

FDA Vaccines 40

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. 52% of RSAs focus on oncology RSAs are predominantly arranged within oncology (52%) since these drugs typically rely on RSAs to gain reimbursement. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

FDA 105

FDA 105

European Pharmaceutical Review

DECEMBER 9, 2022

billion by 2027 during the forecast period, due to the rise in ongoing clinical trials for oligonucleotide-based therapies in key therapeutic sectors such as oncology. Tag Copenhagen A/S (Denmark). According to a new market report by ResearchAndMarkets, the global oligonucleotide synthesis market is projected to reach $16.7 CSBIO (US).

Compounding 91

Compounding 91

pharmaphorum

JANUARY 11, 2021

US biotech bluebird bio has announced plans to split into two this year, with a separate oncology business spinning off as the company prepares to bring its products to market. Meanwhile the as-yet unnamed oncology company will spin off under the leadership of bluebird’s current chief executive Nick Leschly. million price tag.

FDA 63

FDA 63

pharmaphorum

JANUARY 24, 2022

IBM said the sell-off is tagged as “a clear next step” as it focuses on its platform-based hybrid cloud and artificial intelligence strategy, but it’s no secret that Watson Health has failed to live up to its early promise.

Cerner 110

Cerner 110

pharmaphorum

APRIL 27, 2022

AZ’s head of oncology R&D Susan Galbraith said the breakthrough designation “is a significant validation of the potential we see for the historic DESTINY-Breast04 trial to enable a paradigm shift in how breast cancer is classified by targeting the full spectrum of HER2 expression.”

Chemotherapy 58

Chemotherapy FDA 58

Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000.

Immunization 52

Immunization Vaccines 52

pharmaphorum

APRIL 20, 2021

NICE’s final appraisal document for Kesimpta will be followed by technology appraisal guidance (TAG) that will pave the way for NHS prescribing in England and Wales. The Scottish Medicines Consortium is expected to publish its final advice on the drug later this year. billion in sales in 2028.

Hospitals 110

Hospitals Documentation 110

European Pharmaceutical Review

AUGUST 24, 2022

In total, there are 14 approved ADCs on the global market, all for oncology indications, and over 140 ADCs currently in clinical development. tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs. Nature Reviews Clinical Oncology. cancer agent or disease-relevant toxin.

Compounding 87

Compounding Pharmaceutical Companies Pharmaceutical Companies 87

PharmaShots

MARCH 9, 2023

Birthplace: Belén was born in Almansa (Spain) Additional Information: Merck became a significant international participant in immunology, oncology, and immune oncology under her leadership of the Healthcare business. and Banco Bilbao Vizcaya Argentaria S.A LinkedIn Total experience: 16 yrs.

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

pharmaphorum

OCTOBER 4, 2022

The companies tasked with supporting the data needs of the Biobank are Medidata and Theradex Oncology, alongside the NCI. The author of the study noted that researchers from anywhere in the world can now request access to the growing dataset that is being generated by the Biobank effort. Up in the clouds.

Documentation 105

Documentation Data Entry HIPAA Insurance 105

European Pharmaceutical Review

NOVEMBER 10, 2022

BT-474 cell line was gene-edited to incorporate a green fluorescent protein (GFP) tag into late endosomes/lysosomes (green). Figure 2 : Super-resolution imaging of CRISPR/Cas9 reporter cell lines enables visualisation of cellular uptake of complex medicines. Physical characterisation.

Labelling 100

Labelling Compounding 100

The Physician Pharmacist

SEPTEMBER 14, 2023

Just for example, I loved oncology class. I in that I did a Clinical Oncology rotation at the Johns Hopkins Hospital in Baltimore, and hated it. It's funny because I remember, you know, my Hopkins rotation and I absolutely loved my oncology, you know, rotation, but you're the opposite of that. But I also hated cardiology.

Medical Schools 52

Medical Schools Hospitals Communication Patient Care 52

European Pharmaceutical Review

DECEMBER 27, 2023

This is in addition to its considerable price tag. About the author Professor Arnon Nagler, MD is President of the Hemato-Oncology Center and director of the Division of Hematology and the Bone Marrow Transplantation and Cord Blood Bank at the Sheba Medical Center, and Professor of Medicine at Tel Aviv University in Israel. 2019;12(1).

Adverse Reactions 88

Adverse Reactions Immunization Medical Schools Chemotherapy 88

Pharmaceutical Technology

MARCH 17, 2023

Between 2012 and 2022, the number of oncology risk sharing agreements increased massively by 498%. Watt said risk sharing agreements in oncology made up almost 50% of all pharmaceutical risk sharing agreements, as per a GlobalData analysis. This may be because access to oncology drugs varies widely across the world, she added.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Communication 102